A Smarter Way to Evaluate Protein Therapeutics— Expedited, Reliable Pharmaceutical Development Agilent case study The drug discovery process has been continuously refined over the years. However, the basic approach remains largely unchanged despite many technological advancements. So, some are asking, "Is it time to fundamentally modify the way we approach new pharmaceutical development?" A team at the University of Michigan, led by Brandon Ruotolo, professor of chemistry, believes it is, and they think they have the right tool for the job: the new Agilent 6560C Ion Mobility LC/Q-TOF. Ruotolo and team partnered with Agilent scientists to expand the capabilities of the platform to enable deeper protein characterization, which has the potential to revolutionize the development p

Join for free to read